Angiodynamics (ANGO): SVP Quality and Regulatory bought ~$608

~$608

Approx. value · 100 sh @ $6.08

46K

Holds after · shares reported

Traded

Oct 10, 2024

Filed

Oct 10, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 7, 2024Insider · 2 peopleInsiders: 2 purchases (~$125K)
2. Oct 8, 2024InsiderCFO purchased ~$10K of ANGO shares in the open market
3. Oct 10, 2024 · this disclosureInsiderOfficer purchased ~$608 of ANGO shares in the open market

What came next

1. Jan 16, 2025InsiderOfficer sold ~$50K of ANGO shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Angiodynamics

For Angiodynamics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANGO page.

Other recent filings by Warren Jr Nighan, SVP Quality and Regulatory

• SEC Form 4 at Angiodynamics (ANGO)Jan 17, 2025
• SEC Form 4 at Angiodynamics (ANGO)Oct 10, 2024

The full history of Warren Jr Nighan, SVP Quality and Regulatory is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Angiodynamics

• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 30, 2026
• SEC Form 144Oct 29, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its ANGO page.